By Iain Gilbert
Date: Wednesday 24 Apr 2024
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.
Transaction in Own Shares | 26-Apr-2024 | 17:49 | RNS |
Notification of Major Holdings | 26-Apr-2024 | 15:39 | RNS |
Form 8.3 - Spirent Communications plc | 26-Apr-2024 | 15:20 | RNS |
Form 8.3 - Spirent Communications plc | 26-Apr-2024 | 14:57 | RNS |
Form 8.3 - The Vanguard Group, Inc.: Spirent Com... | 26-Apr-2024 | 14:54 | EQS Group |
Questor:Meggitt | 23-Dec-2014 | Telegraph |
Questor :KCOM | 27-Nov-2014 | Telegraph |
Questor :Ricardo | 31-Oct-2014 | Telegraph |
Questor:CSR | 17-Oct-2014 | Telegraph |
Questor:BAE Systems | 03-Sep-2014 | Telegraph |
Price | 4,550.23 |
Change Today | 34.68 |
% Change | 0.77 % |
26-Apr-24 Close | 4,550.23 |
You are here: research